- Home
- GKOS
GKOS
Glaukos Corporation
as of 03-11-2026 3:58pm EST
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | ALISO VIEJO |
| Market Cap: | 6.9B | IPO Year: | 2015 |
| Target Price: | $133.07 | AVG Volume (30 days): | 662.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.28 | EPS Growth: | -18.41 |
| 52 Week Low/High: | $73.16 - $130.23 | Next Earning Date: | N/A |
| Revenue: | $507,442,000 | Revenue Growth: | 32.33% |
| Revenue Growth (this year): | 23.39% | Revenue Growth (next year): | 27.46% |
| P/E Ratio: | -31.58 | Index: | N/A |
| Free Cash Flow: | -22455000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Glaukos Corporation (GKOS)
Director
Avg Cost/Share
$117.05
Shares
15,000
Total Value
$1,760,761.43
Owned After
26,411
Director
Avg Cost/Share
$127.97
Shares
15,000
Total Value
$1,915,576.23
Owned After
37,449
PRESIDENT & COO
Avg Cost/Share
$127.62
Shares
10,498
Total Value
$1,340,379.78
Owned After
100,458
CHAIRMAN & CEO
Avg Cost/Share
$115.00
Shares
186,945
Total Value
$21,498,675.00
Owned After
153,775
SEC Form 4
CHAIRMAN & CEO
Avg Cost/Share
$115.00
Shares
88,055
Total Value
$10,126,325.00
Owned After
153,775
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| WEISNER AIMEE S | GKOS | Director | Feb 19, 2026 | Sell | $117.05 | 15,000 | $1,760,761.43 | 26,411 | |
| Stapley Marc | GKOS | Director | Jan 22, 2026 | Sell | $127.97 | 15,000 | $1,915,576.23 | 37,449 | |
| Gilliam Joseph E | GKOS | PRESIDENT & COO | Jan 22, 2026 | Sell | $127.62 | 10,498 | $1,340,379.78 | 100,458 | |
| Burns Thomas William | GKOS | CHAIRMAN & CEO | Jan 16, 2026 | Sell | $115.00 | 186,945 | $21,498,675.00 | 153,775 | |
| Burns Thomas William | GKOS | CHAIRMAN & CEO | Jan 8, 2026 | Sell | $115.00 | 88,055 | $10,126,325.00 | 153,775 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 17, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYFeb 17, 2026 · 100% conf.
1D
+3.09%
$109.94
Act: +13.47%
5D
+10.93%
$118.30
Act: +11.75%
20D
+14.92%
$122.55
Glaukos Corporation_February 17, 2026 0001192448false00011924482026-02-172026-02-17
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2026
Glaukos Corporation (Exact name of registrant as specified in its charter)
Delaware 001-37463 33-0945406
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
One Glaukos Way
Aliso Viejo
California 92656
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (949) 367-9600 Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of each class: Trading Symbol Name of each exchange on which registered:
Common Stock
GKOS
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On February 17, 2026, Glaukos Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such filing. Item 7.01. Regulation FD Disclosure.
A Quarterly Summary containing supplemental business and financial information for the Company’s fourth quarter and fiscal year ended December 31, 2025 is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein. A copy of the Quarterly Summary is also available in the “Financials & Filings” section of the Company’s investor relations website at https://investors.glaukos.com. The information contained in this Item 7.01 and in the accompanying Exhibit 99.2 shall not be deemed filed for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Exchange Act or the Securities Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1
Press Release of Glaukos Corporation, dated February 17, 2026
99.2 Quarterly Summary of Glaukos Corporation for the fourth quarter and fiscal year ended December 31, 2025
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GLAUKOS CORPORATION
(Registrant)
By: /s/ Alex R. Thurman
Name: Alex R. Thurman
Title: Senior Vice President & Chief Financial Officer
Date: February 17, 2026
2025 Q4 Q4 2025 Earnings
8-K BUY Jan 13, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYJan 13, 2026 · 100% conf.
1D
+3.09%
$109.94
Act: +13.47%
5D
+10.93%
$118.30
Act: +11.75%
20D
+14.92%
$122.55
Glaukos Corporation_January 13, 2026 0001192448false00011924482026-01-132026-01-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2026
Glaukos Corporation (Exact name of registrant as specified in its charter)
Delaware 001-37463 33-0945406
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
One Glaukos Way Aliso Viejo, California 92656
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (949) 367-9600 Not Applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act:
Title of each class: Trading Symbol Name of each exchange on which registered:
Common Stock
GKOS
New York Stock Exchange
Item 2.02. Results of Operations and Financial Condition. On January 13, 2026, Glaukos Corporation (the “Company”) issued a press release announcing its preliminary, unaudited net sales results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such filing. Item 7.01. Regulation FD Disclosure. The Company intends to present the materials attached as Exhibit 99.2 to this Current Report on Form 8-K (the “Investor Presentation”) from time to time in presentations to investors and other stakeholders. The Investor Presentation will also be available on the investor page of the Company’s website at http://investors.glaukos.com. The information contained in this Item 7.01 and in the accompanying Exhibit 99.2 shall not be deemed filed for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Exchange Act or the Securities Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description
99.1 Press Release of Glaukos Corporation dated January 13, 2026
99.2
Investor Presentation, dated January 2026
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GLAUKOS CORPORATION
(Registrant)
By: /s/ Alex R. Thurman
Name: Alex R. Thurman
Title: Senior Vice President & Chief Financial Officer
Date: January 13, 2026
2025 Q3 Q3 2025 Earnings
8-K Oct 29, 2025
Q3 2025 Earnings
8-KOct 29, 2025
Glaukos Corporation_October 29, 2025 0001192448false00011924482025-10-292025-10-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2025
Glaukos Corporation (Exact name of registrant as specified in its charter)
Delaware
001-37463
33-0945406
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
One Glaukos Way
Aliso Viejo
California 92656
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (949) 367-9600 (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of each class:
Trading Symbol
Name of each exchange on which registered:
Common Stock
GKOS
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On October 29, 2025, Glaukos Corporation (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such filing. Item 7.01. Regulation FD Disclosure. A Quarterly Summary containing supplemental business and financial information for the Company’s third quarter ended September 30, 2025 is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein. A copy of the Quarterly Summary is also available in the “Financials & Filings” section of the Company’s investor relations website at https://investors.glaukos.com. The information contained in this Item 7.01 and in the accompanying Exhibit 99.2 shall not be deemed filed for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Exchange Act or the Securities Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.
Description
99.1
Press Release of Glaukos Corporation, dated October 29, 2025
99.2 Quarterly Summary of Glaukos Corporation for the third quarter ended September 30, 2025
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GLAUKOS CORPORATION
(Registrant)
By: /s/ Alex R. Thurman
Name: Alex R. Thurman
Title: Senior Vice President & Chief Financial Officer
Date: October 29, 2025
Compare GKOS vs Leading Stocks
See how GKOS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GKOS Glaukos Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.